{Reference Type}: Case Reports
{Title}: A case report of thrombocytopenic COVID-19 and Miller-Fisher syndrome on a concurrent chronic immune neuropathy.
{Author}: Blackbourn L;Hamid U;Tokala J;Blume G;
{Journal}: Medicine (Baltimore)
{Volume}: 103
{Issue}: 21
{Year}: 2024 May 24
{Factor}: 1.817
{DOI}: 10.1097/MD.0000000000038304
{Abstract}: <B>BACKGROUND: </B>Miller-Fisher syndrome (MFS) is a rare subtype of Guillain-Barre syndrome with classic features of ataxia, areflexia, and ophthalmoplegia that can be caused by a preceding infection including COVID-19. We present a current, asymptomatic thrombocytopenic COVID-19 infection as a cause of MFS in a 60-year-old male with a concurrent chronic immune neuropathy.<BR><B>METHODS: </B>A 60-year-old male presenting with acute symptoms of MFS including ataxia, areflexia, and ophthalmoplegia on a chronic immune neuropathy for at least 1 year and concurrent asymptomatic COVID-19 positive infection.<BR><B>METHODS: </B>MFS suspected secondary to a current thrombocytopenic COVID-19 infection.<BR><B>METHODS: </B>Five days of intravenous immune globulin with continued monthly intravenous immune globulin as an outpatient, follow-up long-term in a neuromuscular clinic, electromyography as an outpatient, and continued physical therapy.<BR><B>RESULTS: </B>The patient significantly improved after initial treatment.<BR><B>CONCLUSIONS: </B>The full effect of COVID-19 on the various Guillain-Barre syndrome subtypes is unknown, although it clearly can be a cause of the various variants including being caused by a current, asymptomatic infection.